<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218880</url>
  </required_header>
  <id_info>
    <org_study_id>M2ES2010-1</org_study_id>
    <nct_id>NCT01218880</nct_id>
  </id_info>
  <brief_title>Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase I Study of M2ES Combined Gemcitabine in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protgen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protgen Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I trail will be conducted to evaluate the safety of M2ES in combination with
      gemcitabine in locally advanced or metastatic pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I trail will be conducted to determine the MTD and safety of M2ES(administered
      intravenous infusion on Days 1,8,15,21of a 28-day cycle) in combination with gemcitabine
      (1000 m/m2). Gemcitabine will be administered as an intravenous infusion on Days 1, 8, and 15
      of each 28-day cycle,at the same time determine the safety and efficiency of this combined
      regime.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerant dose</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>M2ES-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M2ES-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 7.5mg</intervention_name>
    <description>M2ES Dosage：7.5mg/m2</description>
    <arm_group_label>M2ES-A</arm_group_label>
    <other_name>M2ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 15mg</intervention_name>
    <description>M2ES Dosage：15mg/m2</description>
    <arm_group_label>M2ES-B</arm_group_label>
    <other_name>M2ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 30mg</intervention_name>
    <description>M2ES Dosage：30mg/m2</description>
    <arm_group_label>M2ES-C</arm_group_label>
    <other_name>M2ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES 45mg</intervention_name>
    <description>M2ES Dosage：45mg/m2</description>
    <arm_group_label>M2ES-D</arm_group_label>
    <other_name>M2ES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients had histologically or cytologically confirmed pancreatic adenocarcinoma that
             was not amenable to potentially curative surgery.

          2. No prior chemotherapy was allowed.

          3. Prior radiation therapy was allowed provided that the only sites of measurable disease
             were not located within the radiation port.

          4. 18 to 60 years of age

          5. Karnofsky performance status (KPS) of 60-100 points

          6. Unidimensionally measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) criteria

          7. Adequate hematologic, renal, and hepatic function was required as deWned by the
             following: WBC ≥4×109/L, absolute neutrophil count ≥ 1.5×109/L, platelet count
             ≥100×109/L, hemoglobin ≥ 9g/dL, total bilirubin ≤2 upper limit of normal [ULN],AST ≤
             1.5 ULN, or ≤ 3 ULN if there was evidence of liver metastases; alkaline phosphatase ≤
             1.5 ULN, or ≤ 3 ULN if there was evidence of liver Metastases; creatinine clearance
             ≥50 mL/min.

          8. life expectancy of at least 12 weeks.

          9. All patients provided written informed consent according to federal and institutional
             guidelines.

        Exclusion Criteria:

          1. patients had clinically apparent CNS disease ( primary brain tumors, tumor related
             apoplexy, CNS metastases, carcinomatous meningitis.)

          2. another active malignancy, or any history of other malignancy within the past 5 years
             except for nonmelanoma skin cancer and carcinoma in situ of the cervix.

          3. more than 4 weeks intervals between the last administration of the targeted therapy
             regimen and study entry.

          4. radiation therapy have not been completed 4 weeks before enrollment.

          5. major surgery within the prior 4 weeks;

          6. participating any clinical trial within the prior 4 weeks;

          7. Pregnant or lactating women.

          8. tumor involvement of major blood vessels

          9. uncontrolled intercurrent illness as following: prior or ongoing uncontrolled
             hypertension;angina pectoris; congestive cardiac failure; myocardial ischemia,
             infarction, uncompensated coronary artery disease within the past 6 months;
             Uncontrolled arrhythmia; Uncontrolled diabetes mellitus; Uncontrolled infection.

         10. chronic renal disease.

         11. urine protein ≥ 500 mg in 24 hours;

         12. prior history of gastrointestinal bleeding, hemoptysis, bleeding diathesis.

         13. pulmonary embolus, or deep venous thrombosis

         14. ECG: QTC ≥ 480 ms

         15. Patients on therapeutic doses of heparin or antiplatelet agents.

         16. Patients who received thrombolytic agents or who required full-dose anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaosheng Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changhai Hosptial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaosheng Li, MD</last_name>
    <phone>8621-81873241</phone>
    <email>zhsli@81890.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaosheng Li, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guodong Chang</name_title>
    <organization>Protgen Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

